Infusion-related reactions (IRRs) elicited by therapeutic antibodies are commonly observed in the treatment of hematologic malignancies. In contrast to the currently approved type 1 anti-CD20 monoclonal antibodies (mAb) rituximab and ofatumumab, obinutuzumab is different by virtue of being a type 2 anti-CD20 mAb with increased capacity to induce direct cell death. [1] [2] [3] [4] [5] The fragment crystallisable (Fc) portion is glycoengineered (afucosylated), which increases its binding affinity to FcγRIIIA and FcγRIIIB, 1,2 enhancing antibody dependent cellular cytotoxicity and phagocytosis with less complement activation.
In the CLL11 trial (NCT01010061, 'stage 2'), patients with previously untreated chronic lymphocytic leukemia (CLL) and co-morbidities were randomized to receive either rituximab or obinutuzumab administered in combination with chlorambucil. 6, 7 In the head-to-head comparison of the two antibody-containing regimens, obinutuzumab treatment resulted in a statistically significant improvement in efficacy endpoints. However, this improvement was accompanied by an increase in IRRs, with higher overall incidence and severity when compared with the rituximab-treated arm but largely limited to the first infusion. These IRRs had clinical importance resulting in a 7% discontinuation rate in the obinutuzumab-treated cohort, compared with o1% for rituximab. Predisposing biologic and clinical risk factors for IRRs are not well defined. In an attempt to better understand the profile of patients with CLL at particular risk of IRRs, we used this large clinical data set to perform a multivariate analysis.
Patients treated with a first infusion of obinutuzumab (n = 331) or rituximab (n = 326) were included. Plausible baseline risk factors were identified a priori and included parameters of disease burden, patient-specific factors such as age, concurrent medications and co-morbidities, FcγR genotype and baseline laboratory values. The primary outcome, development of IRR with the first infusion, was defined as the occurrence of related signs and symptoms during or within 24 h of administration.
Multivariable logistic regression models were fit to assess associations between patient characteristics and early IRR. The robustness of the model generated was then internally verified using bootstrapping techniques. A landmark analysis was performed to evaluate the impact of early IRR on progressionfree survival (PFS) in both groups and Kaplan-Meier curves were used to illustrate the estimated conditional progression-free probabilities. All statistical analyses were conducted in SAS (SAS Institute, Cary, NC, USA).
The incidence of any grade IRR with the first infusion (all grades) was 65% (214/331) in the obinutuzumab-treated cohort and 27% (88/326) in the rituximab-treated cohort. Severe IRR (grade ⩾ 3) events were seen in 20% (65/331) of patients treated with obinutuzumab and 3% (10/326) in the rituximab arm; there were no fatal IRRs. The features at baseline associated with increased risk of developing an IRR from obinutuzumab or rituximab were: higher density of CD20 expression on CD19+CD5+ CLL cells, increased CD16 (FcγRIIIA) expression on circulating CD56+ natural killer (NK) cells, palpable splenomegaly, higher absolute lymphocyte count (ALC) in peripheral blood (PB), neutropenia, a higher affinity FcγR genotype (VV or VF versus FF) and the presence of an underlying respiratory co-morbidity. Odds ratios (ORs) and 95% confidence intervals (CIs), based on complete case analysis, are presented in Table 1 .
Since IRRs were more frequent and severe in obinutuzumabtreated patients, we next focused on this group exclusively. If patients treated with rituximab were excluded from the data set, the variable that contributed most to the probability of developing an IRR was the density of CD20 expression on CLL cells in PB as expressed by the mean fluorescent intensity (MFI) generated by flow cytometric analysis pre-treatment (OR 3.6, 95% CI 1.6-7.9). In addition, MFI of CD16 (OR 2.2, 95% CI 0.8-5.6) on gated NK cells and the presence of a palpable spleen (OR 1.1, 95% CI 0.98-1.2) retained significance. Other variables including baseline neutrophil count, ALC, the presence of respiratory co-morbidities and FcγR genotype did not appear to influence outcome to the same degree when rituximab-treated patients were excluded.
To externally validate the importance of CD20 MFI as a risk factor, data from any available prior trials involving and NCT00281918 10 ). Only severe (grade ⩾ 3) IRRs were analyzed as grades 1 and 2 had not been collected uniformly in all the trials available. Results were standardized and plotted for those patients treated with either obinutuzumab or rituximab and those patients who experienced reactions were identified (Supplementary Figure 1) . Patients with higher baseline expression CD20 on their CLL cells were at greater risk for severe grade early IRR, especially those patients treated with obinutuzumab (P = 0.02).
As MFIs for CD20 and CD16 are not standardized or routinely available outside the setting of clinical trials, we performed a separate analysis on the CLL11 data set excluding the immunophenotyping data, with a focus on the obinutuzumabtreated patients only. The resulting model was significant for the presence of trisomy 12 being associated with increased risk To assess if the development of early IRR influenced outcome for patients treated with anti-CD20 mAbs, a landmark analysis was performed starting at study day 3 to eliminate the impact of patients who discontinued immediately with the first infusion. Prognostic factors at baseline that might otherwise influence PFS 11 were relatively balanced across all groups (Supplementary Table 1 ). For patients treated with rituximab (Figure 1a) , there appeared to be a statistically significant benefit conferred, with improved PFS in those patients who experienced an early IRR (hazard ratio (HR) 0.6, 95% CI 0.4-0.8, P = 0.002). For those patients treated with obinutuzumab, all patients had improved PFS compared with those treated with rituximab, but there appeared to be no benefit from having an early IRR in this cohort (HR 1.5, 95% CI 1.0-2.4, P = 0.07) with no statistically significant difference between the two groups (Figures 1b). Including only patients that received all six cycles of therapy yielded similar results-a statistically significant benefit seen in those who experienced early IRR treated with rituximab (HR 0.7, 95% CI 0.5-0.9, P = 0.01) but no significant difference seen in those treated with obinutuzumab (HR 1.5, 95% CI 0.9-2.6, P = 0.1; Figures 1c and d) .
This analysis, based on a large number of treatment-naïve CLL patients, has identified novel disease-and patient-specific biologic variables that appear to play a role in the development of IRR with anti-CD20 mAbs. Increased expression of CD20 on the surface of CLL cells at baseline was found to be a consistently important determinant of risk, a finding that we were able to validate with both internal and external data sets. When this variable was excluded for obinutuzumab-treated patients, the presence of Trisomy 12, known to be associated with higher levels of CD20 expression in CLL 12,13 became statistically significant. In the absence of standardized methods of assessing and reporting CD20 MFI at the present time, this cytogenetic abnormality may prove a useful surrogate to identify patients at particular risk of IRR.
The risk factors of greatest importance would suggest that IRR result from enhanced binding of anti-CD20 biologics to both malignant B-cells and the FcγR of NK cells. The natural conclusion was that this would result in greater cytotoxicity and improvements in progression-free outcomes for patients. Increased levels of CD20 expression have been correlated with improved response to therapy, 14 and for those patients treated with rituximab, the development of IRR was associated with improved response. However for patients treated with obinutuzumab, although PFS curves demonstrated consistent superiority over rituximab, the development of IRR did not appear to confer significant advantage in PFS in our analysis. The occurrence of IRR in rituximab-treated patients may well herald improved efficacy, whereas this improved efficacy was observed in all patients treated with the more potent type 2 antibody obinutuzumab, in whom the majority (66%) experienced IRR. It is important to acknowledge that patients were not randomized to having an IRR and this hypothesis generating analysis will need to be further evaluated.
Our results support the idea that higher rates of IRR seen with the administration of obinutuzumab result from cellular activation and enhanced cross-linking between CD20 expressing leukemic cells and FcγRIIIA bearing effector cells-an on-target effect. As external validation was limited and models were derived using a single data set, these results will need to be corroborated with the generation of further patient data from ongoing clinical studies. The improvement in antibody technology realized by obinutuzumab can confer benefit to more patients if we can better understand how to predict, manage and prevent IRR. This is currently the subject of evaluation in ongoing clinical trials (NCT01905943 and NCT02336048) and these results may shed more light on how best to prevent this immunologic phenomenon.
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1,2 The prevalence of MGUS increases with age, and in predominantly white populations, it increases from 3% at age 60 years to 9% at age 80-89 years. 3 MGUS is a precursor condition for multiple myeloma (MM) and light chain amyloidosis, which are progressive conditions with a fatal outcome. Both MGUS and MM show familial clustering among and between these diseases, suggesting that they share genetic susceptibility; MGUS is also related to some other malignancies of the B-cell lineage. [4] [5] [6] [7] Known nongenetic risk factors of MGUS include prior infections and exposure to herbicides. [8] [9] [10] Studies on the association of MGUS with personal or familial autoimmune diseases (ADs) have shown several associations for personal history, whereas for family history of combined ADs, the risk of 1.1 was reported. 9, 11 For MM, both personal and family histories with certain ADs have been identified. 9, 11, 12 However, the risk for MM has been overall small (1.1), and found only in ankylosing spondylitis and systemic sclerosis patients. 12 For the present study, we identified 12 140 MGUS patients from Swedish nationwide hospital records, and from the same sources, we identified 769 991 patients with any of 43 ADs. Combining these into a nationwide family register, we provide familial risk for MGUS patients whose first-degree relatives were diagnosed with ADs. Conversely, we also calculated risks for AD patients whose family members were diagnosed with MGUS to yield a largely independent risk estimate. Because of large sex-preference among ADs, sex-specific familial risks were also shown.
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